Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;22(3):180-185.
doi: 10.1093/ijnp/pyz002.

Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder

Zhenhao Shi  1 , Kanchana Jagannathan  1 , An-Li Wang  1   2 , Victoria P Fairchild  1 , Kevin G Lynch  1 , Jesse J Suh  1 , Anna Rose Childress  1 , Daniel D Langleben  3   4
Affiliations

Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder

Zhenhao Shi et al. Int J Neuropsychopharmacol. .

Abstract

Adherence is a major factor in the effectiveness of the injectable extended-release naltrexone as a relapse prevention treatment in opioid use disorder. We examined the value of a variant of the Go/No-go paradigm in predicting extended-release naltrexone adherence in 27 detoxified opioid use disorder patients who were offered up to 3 monthly extended-release naltrexone injections. Before extended-release naltrexone, participants performed a Go/No-go task that comprised positively valenced Go trials and negatively valenced No-go trials during a functional magnetic resonance imaging scan. Errors of commission and neural responses to the No-go vs Go trials were independent variables. Adherence, operationalized as the completion of all 3 extended-release naltrexone injections, was the outcome variable. Fewer errors of commission and greater left accumbal response during the No-go vs Go trials predicted better adherence. These findings support the clinical potential of the behavioral and neurophysiological correlates of response inhibition in the prediction of extended-release naltrexone treatment outcomes in opioid use disorder.

Keywords: adherence; errors of commission; extended-release naltrexone; nucleus accumbens; opioid use disorder.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Receiver operating characteristic (ROC) curves for the logistic regression models predicting adherence to 3 months of extended-release naltrexone (XR-NTX) treatment in opioid use disorder. (A) Fewer errors of commission predicted better adherence to XR-NTX; area under the ROC curve (ROC-AUC) = 0.79, 95% bootstrap confidence interval (BootCI) = [0.58,0.93]. (B) Greater left nucleus accumbens response to the No-go vs Go trials predicted better adherence to XR-NTX; ROC-AUC = 0.82, 95% BootCI = [0.53,0.96].
See this image and copyright information in PMC

References

    1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
    1. Aron AR, Robbins TW, Poldrack RA (2014) Inhibition and the right inferior frontal cortex: one decade on. Trends Cogn Sci 18:177–185. - PubMed
    1. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Stat Method) 57:289–300.
    1. Chen M, Bargh JA (1999) Consequences of automatic evaluation: immediate behavioral predispositions to approach or avoid the stimulus. Pers Soc Psychol Bull 25:215–224.
    1. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O’Brien CP (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63:210–218. - PMC - PubMed

Publication types

MeSH terms